IGF-1 c.258 A > G synonymous mutation ameliorates senile osteoporosis.
Abstract
Senile osteoporosis (SOP) is a multifactorial, age-related progressive phenomenon with a considerable morbidity and mortality. IGF-1 is an important regulator of bone reconstruction and metabolism throughout life. Nevertheless, our previous study unexpectedly found there is no change in the peak bone mass with a altered IGF-1 gene expression leaded by IGF-1 c.258 A > G synonymous mutation. Considering its involvement in the cellular senescence, we suspected c.258 A > G may participate in SOP. Therefore, the effect of IGF-1 c.258 A > G on SOP was firstly detected, the changes of bone formation and bone resorption index in SOP mice with two genotypes indicated it improved SOP. Then, the in vitro study confirmed the mutation ameliorates SOP by promoting the growth and development of senescent osteoblasts. At last, co-culture of osteoblast and osteoclast further verified the mutation prevents SOP by increasing the bone formation capacity of senescent osteoblasts. Collectively, this study illuminated the role of IGF-1 c.258 A > G in ameliorating SOP.
The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.
Research summary
The paper investigates the role of a specific IGF-1 mutation in ameliorating senile osteoporosis, which is an age-related condition. While it touches on a mechanism that could be linked to aging processes, the focus is primarily on a specific mutation's effect on a disease rather than addressing the root causes of aging or lifespan extension. The findings may contribute to understanding bone health in the elderly, but the overall impact on the broader field of longevity research is limited.
Author of this paper? Send a correction.